KAER Biotherapeutics specializes in Single-Pass Low-Shear Aerosol Generation nozzle technology and has developed a new class of aerosol delivery system for the treatment of respiratory and other diseases. KAER has developed and incorporated a new class of uncloggable single-pass nozzles into its SUPRAER technology. SUPRAER generates liquid aerosols that are rapidly evaporated and delivered as concentrated dry fine particle aerosols. Both solutions of large molecules and suspensions with viscosities up to at least 40 cSt can be readily aerosolized at lower pressures than with other atomizers. Dry particle aerosols less than 4 μm mass median aerodynamic diameter, MMAD, can be generated from agents such as 20% 8kDa PVP, as a drug or protein surrogate, at an output rate of 250 mg/min with over 50% efficiency. Surfactant aerosols of less than 4 μm MMAD can be delivered for the first time at output rates over 100 mg/min (to treat acute lung injury and acute respiratory distress). The particles generated have a relatively narrow size distribution with typical geometric standard deviations between 1.5 and 2. These nozzles, together with KAERâs advanced focused-flow nozzles, enable SUPRAER to generate respirable fine particle aerosols from sparsely soluble agents as well as high concentrations of large molecules or suspensions such as monoclonal antibodies, anti-infectives and anticancer agents. The final size of these aerosols can be tailored for optimum deposition in the lungs of small and large animals as well as humans. This new development adds to KAERâs worldwide intellectual property portfo
